FFTY vs VTI
CapForce IBD 50 ETF vs Vanguard Morningstar Total Stock Market ETF
Which is better, FFTY or VTI?
Mid Cap Growth against Large Cap Blend.
VTI has a lower expense ratio. VTI led over 1Y, 3Y, 5Y and the full window. VTI is less concentrated, with 33.3% of the fund in its ten largest positions against 35.1%.
MarketXLS is not an investment adviser. This comparison is generated automatically from market data and is for information only. A Best mark means the better reading on that one measure, not a recommendation to buy.
Side-by-Side Comparison
| Metric | FFTY | VTI |
|---|---|---|
| Expense Ratio | 0.80% | 0.03%Best |
| AUM | $71M | $666.9B |
| Dividend Yield | 1.29% | 1.03% |
| Holdings | 52 | 3,543 |
| YTD Return | +0.76% | +13.60%Best |
| 1Y Return | -3.14% | +18.17%Best |
| 3Y Return (annualized) | +18.24% | +23.04%Best |
| 5Y Return (annualized) | -5.89% | +12.14%Best |
| Volatility (annualized) | 24.3% | 15.5%Best |
| Max Drawdown | -59.5% | -35.0%Best |
| $10,000 over 5 years | $7,382 | $17,734Best |
| Top 10 Weight | 35.1% | 33.3%Best |
| Fund Family | Capital-FORCE ETF | Vanguard (US) |
| Category | Equity | Equity |
| Style | Mid Cap Growth | Large Cap Blend |
| Inception | Apr 8, 2015 | May 24, 2001 |
Volatility and max drawdown are measured over the window both funds cover: Apr 9, 2015 to Sep 25, 2026 (11.5 years).
FFTY vs VTI growth
Month-end closes. Both lines start at 0% in the first month shown, so the gap between them is the difference in growth across that window. The full view covers the 11.5 years both funds cover.
FFTY vs VTI Performance
CapForce IBD 50 ETF (FFTY) is an ETF from Capital-FORCE ETF and Vanguard Morningstar Total Stock Market ETF (VTI) is an ETF from Vanguard (US). Over the past year FFTY returned -3.14% while VTI returned +18.17%. Year to date, FFTY is up 0.76% versus a gain of 13.60% for VTI.
Over three years, FFTY compounded at +18.24% per year against +23.04% for VTI; over five years the annualized figures are -5.89% and +12.14% respectively. Across the full 12-year window we track, VTI has the edge at +12.29% annualized vs +3.55%.
Past performance does not guarantee future results.
Risk: Volatility and Drawdowns
FFTY has been the more volatile fund, with annualized monthly volatility of 24.3% compared with 15.5% for VTI. Lower volatility generally means a smoother ride, though it often comes with lower long-run returns.
The deepest peak-to-trough decline in our data was -59.5% for FFTY and -35.0% for VTI. Drawdown depth is what each fund did in the worst stretch of the window measured above.
The two funds' monthly returns correlate at 0.80. They usually move together, but the gap leaves some room for diversification.
Fees and Cost Over Time
FFTY charges 0.80% per year while VTI charges 0.03%. On a $10,000 position that is $80 vs $3 annually, a gap of $77 per year that compounds over a long holding period. On income, FFTY currently yields 1.29% against 1.03% for VTI.
Holdings Overlap
71.0% of FFTY's money is in holdings VTI also owns. 1.2% of VTI's money is in holdings FFTY also owns.
Most of FFTY is already inside VTI. Owning both mostly buys the same companies twice.
35 positions in common, counted across the 50 positions we hold weights for in FFTY and 3,463 in VTI, against full books of 52 and 3,543.
What only one of them owns
Our book lists 1,124 positions for VTI that do not appear in our book for FFTY (96.3% of the fund), and 4 for FFTY that do not appear in VTI (9.8%).
Some of those will be the same company recorded under a different code in one of the two books, so the real difference in what you would own is no larger than this and may be smaller. We do not name the individual positions here for that reason.
Top Shared Holdings
| Stock | Weight in FFTY | Weight in VTI | Difference |
|---|---|---|---|
| TGTXTg Therapeutics Inc Common Stock | 3.73% | 0.01% | 3.72% |
| KNSA:LNKiniksa Pharmaceuticals International, Plc | 3.69% | 0.00% | 3.69% |
| HNGEHinge Health Inc | 3.64% | 0.00% | 3.64% |
| WETFWisdomtree International Equity | 3.61% | 0.00% | 3.61% |
| TVTXTravere Therapeutics Inc | 3.58% | 0.01% | 3.57% |
| ETONEton Pharmaceuticals Inc. | 3.53% | 0.00% | 3.53% |
| NTRANatera Inc | 3.47% | 0.05% | 3.42% |
| DAVEDave Inc. | 3.35% | 0.01% | 3.34% |
| HALOHalozyme Therapeutics Inc | 3.15% | 0.01% | 3.14% |
| GKOSGlaukos Corp. | 3.07% | 0.01% | 3.06% |
71.0% of FFTY is already inside VTI.
You probably hold more than these two. Add the rest and see how much of the whole book is the same companies twice.
Free for up to 10 holdings. No account needed.
Frequently Asked Questions
Which is cheaper, FFTY or VTI?
FFTY has an expense ratio of 0.80% while VTI charges 0.03%. VTI is the cheaper option, by $77 a year on a $10,000 investment.
Which performed better, FFTY or VTI?
Over the past year FFTY returned -3.14% vs +18.17% for VTI, so VTI leads on 1-year performance. Over the longest common window we track (12 years), FFTY annualized +3.55% vs +12.29% for VTI. Past performance does not guarantee future results. This is information, not a recommendation.
Which is riskier, FFTY or VTI?
FFTY has been the more volatile fund at 24.3% annualized versus 15.5% for VTI. Worst drawdown: FFTY -59.5% vs VTI -35.0%.
Should I hold both FFTY and VTI?
FFTY and VTI have a monthly-return correlation of 0.80, so their returns are far enough apart for the mix to behave differently from either one alone. This is information, not a recommendation.
What is the holdings overlap between FFTY and VTI?
71.0% of FFTY's money is in holdings VTI also owns. 1.2% of VTI's is in holdings FFTY also owns. They hold 35 positions in common, counted across the 50 positions we hold weights for in FFTY and 3,463 in VTI.
Which pays a higher dividend, FFTY or VTI?
FFTY yields 1.29% while VTI yields 1.03%, so FFTY currently pays the higher dividend yield.
Is VTI better than FFTY?
VTI has a lower expense ratio. VTI led over 1Y, 3Y, 5Y and the full window. VTI is less concentrated, with 33.3% of the fund in its ten largest positions against 35.1%. Which one suits a particular account depends on what it is for. This is information, not a recommendation.